Mass. mover

Alnylam Pharmaceuticals settles legal battle

Alnylam and Tekmira entered a settlement.
Alnylam and Tekmira entered a settlement.

Alnylam Pharmaceuticals Inc., a Cambridge company looking to develop therapeutics based on RNA interference, said it has restructured its relationship with Tekmira Pharmaceuticals with a new licensing agreement. It also said the companies have resolved all litigation between them. Tekmira will receive $65 million, and is eligible to receive $10 million in near-term milestone payments. The litigation involved intellectual property rights of lipid nanoparticle technology, Tekmira said.